Why is the U.S. government investigating GlaxoSmithKline now?
GlaxoSmithKline recently said U.S. enforcement agencies asked for information about third-party advisers the company hired in China during a corruption investigation in the country. The Man From FCPA asks, why now?
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleExperts warn of increased global AML risks as criminals seek to launder Venezuelan money
The U.S. action to remove President Nicolás Maduro of Venezuela and reopen access to the country’s oil reserves will have a significant impact on geopolitics and organized crime activities – creating new challenges for global compliance teams.
-
OpinionCreating effective compliance messages for specific employee groups
As 2026 arrives, have you considered the efficacy of your compliance messaging efforts? We have all seen these compliance taglines “Speak Up!,” “See Something, Say Something,” “Ethics Matter!”
-
ArticleSFO head to step down as speculation grows over future of agency
Nick Ephgrave, director of the U.K.’s main anti-corruption enforcement agency, the Serious Fraud Office, will retire at the end of March—about halfway through his appointed five-year term. Experts say he leaves the agency in a lot better position than he joined it in September 2023.